Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2002

01-07-2002 | Original Article

The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer

Authors: Rachel J. Gibson, Dorothy M. Keefe, Julie M. Clarke, Geoff O. Regester, Fiona M. Thompson, Gary J. Goland, Ben G. Edwards, Adrian G. Cummins

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2002

Login to get access
Metadata
Title
The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer
Authors
Rachel J. Gibson
Dorothy M. Keefe
Julie M. Clarke
Geoff O. Regester
Fiona M. Thompson
Gary J. Goland
Ben G. Edwards
Adrian G. Cummins
Publication date
01-07-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0460-4

Other articles of this Issue 1/2002

Cancer Chemotherapy and Pharmacology 1/2002 Go to the issue

Original Article

Suicide gene therapy using E. coli β-galactosidase

Original Article

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function

Original Article

Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study

Original Article

Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells

Original Article

Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer

Original Article

Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits